AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Cytosolic phospholipase A2 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Cytosolic phospholipase A2 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Cytosolic phospholipase A2, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Cytosolic phospholipase A2. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Cytosolic phospholipase A2. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Cytosolic phospholipase A2 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Cytosolic phospholipase A2
partner:
Reaxense
upacc:
P47712
UPID:
PA24A_HUMAN
Alternative names:
Phospholipase A2 group IVA
Alternative UPACC:
P47712; B1AKG4; Q29R80
Background:
Cytosolic phospholipase A2 (cPLA2), also known as Phospholipase A2 group IVA, plays a pivotal role in membrane lipid remodeling and the biosynthesis of lipid mediators crucial for the inflammatory response. It exhibits calcium-dependent phospholipase and lysophospholipase activities, primarily hydrolyzing the sn-2 position of phospholipids to release arachidonic acid, a precursor for eicosanoid biosynthesis. This enzyme's action is essential for various physiological processes, including embryo implantation and parturition.
Therapeutic significance:
The enzyme's involvement in gastrointestinal ulceration, recurrent, with dysfunctional platelets, underscores its therapeutic significance. Targeting cPLA2 could offer novel treatment avenues for managing this autosomal recessive disorder, characterized by gastrointestinal bleeding, chronic anemia, and platelet dysfunction, by modulating eicosanoid synthesis and inflammatory responses.
